Patents Assigned to China Pharmaceutical University
-
Patent number: 11014895Abstract: A heterocyclic urea compound, and specifically discloses an indoleamine-2,3-dioxygenase inhibitor of a heterocyclic urea compound, which solves the problems of weak curative effect and larger toxic and side effects of existing immunological therapy drugs. The invention further provides a preparation method for an indoleamine-2,3-dioxygenase inhibitor of a heterocyclic urea compound, and an application of the indoleamine-2,3-dioxygenase inhibitor of a heterocyclic urea compound or a pharmaceutically acceptable salt thereof in preparing drugs for treating or preventing tumors.Type: GrantFiled: January 1, 2018Date of Patent: May 25, 2021Assignee: CHINA PHARMACEUTICAL UNIVERSITYInventors: Sheng Jiang, Zhengchao Tu, Haiping Hao, Hequan Yao, Yatao Qiu, Yiwu Yao, Dong Chen
-
Patent number: 10875903Abstract: Bifunctional fusion proteins having Tumstatin active fragments and CD137L extracellular regions are provided. The proteins exhibit activities to inhibit the proliferation of human umbilical vein endothelial cells and to costimulate the proliferation of T cells. They can be used for the treatment of various tumor-related diseases and the regulation of angiogenesis and immunological effects in humans.Type: GrantFiled: May 5, 2014Date of Patent: December 29, 2020Assignee: CHINA PHARMACEUTICAL UNIVERSITYInventors: Shuzhen Wang, Yijun Chen, Dongyang He, Nan Liu, Chao Ma, Zhenyue Gao
-
Application of neuraminidase and inhibitors thereof in myocardial ischemia and myocardial infarction
Patent number: 10639289Abstract: The present invention discloses an application of neuraminidase and inhibitors thereof in myocardial ischemia and myocardial infarction, provides a correlation between neuraminidase and myocardial ischemic damage to prove the myocardial ischemic damage can be alleviated by inhibiting the activity of neuraminidase, and to prove the neuraminidase can be used as a target for screening drugs for preventing, alleviating and/or treating myocardial ischemic damage. The present invention also demonstrates the alleviating effect of neuraminidase inhibitors on myocardial ischemic damage. Neuraminidase inhibitors improves myocardial ischemic damage by reducing the level of neuraminidase. The present invention further provides a pharmaceutical preparation comprising neuraminidase inhibitor(s) and pharmaceutically acceptable carrier(s), the pharmaceutical preparation can be used for reducing the level of neuraminidase, thus improving myocardial ischemic damage.Type: GrantFiled: March 29, 2016Date of Patent: May 5, 2020Assignee: CHINA PHARMACEUTICAL UNIVERSITYInventors: Lianwen Qi, Lei Zhang, Tingting Wei, Yong Fan -
Publication number: 20200062818Abstract: Bifunctional fusion proteins having Tumstatin active fragments and CD137L extracellular regions are provided. The proteins exhibit activities to inhibit the proliferation of human umbilical vein endothelial cells and to costimulate the proliferation of T cells. They can be used for the treatment of various tumor-related diseases and the regulation of angiogenesis and immunological effects in humans.Type: ApplicationFiled: May 5, 2014Publication date: February 27, 2020Applicant: China Pharmaceutical UniversityInventors: Shuzhen WANG, Yijun CHEN, Dongyang HE, Nan LIU, Chao MA, Zhenyue GAO
-
Patent number: 10526370Abstract: A pentapeptide associated with integrin receptor ?v?3, which has a sequence of arginine-tryptophan-arginine-asparagine-methionine. The pentapeptide targets tumor cells highly expressing ?v?3, but not tumor cells lowly expressing ?v?3 and normal cells. Accordingly, the pentapeptide is useful in the diagnosis and treatment of cancers.Type: GrantFiled: October 26, 2015Date of Patent: January 7, 2020Assignee: CHINA PHARMACEUTICAL UNIVERSITYInventors: Yueqing Gu, Congying Zhang, Menglu Zhao, Qian Wang, Caiping Tian, Yuxi Liu
-
Publication number: 20190358345Abstract: The present invention discloses amphiphilic nonsteroid anti-inflammatory platinum nanoparticles, preparation methods therefor and applications thereof. The amphiphilic nonsteroid anti-inflammatory platinum nanoparticle includes an amphiphilic complex formed by coordinating a nonsteroid anti-inflammatory drug and a platinum antitumor drug. Compared with other platinum drugs, the amphiphilic nonsteroid anti-inflammatory platinum prepared according to the present invention can self-assemble into a nanoparticle in an aqueous solution without the addition of an additive or a surfactant. The amphiphilic platinum complex can achieve targeted accumulation of tumor tissues by means of the enhanced permeability and retention effect of the tumor tissues, thereby reducing the side effects of platinum drugs.Type: ApplicationFiled: September 4, 2017Publication date: November 28, 2019Applicant: CHINA PHARMACEUTICAL UNIVERSITYInventors: Hulin JIANG, Lei XING, Chenxi YANG
-
Patent number: 10442759Abstract: Compounds of formula (I) having 1-sulfonamido-4-aryloxy as a basic backbone. A preliminary activity test showed that the compounds provide excellent interference of a binding of Nrf2 by Keap1, thereby activating Nrf2. The compounds have a potential anti-inflammatory activity and can be used to treat a plurality of inflammation-associated diseases, including chronic obstructive pulmonary disease (COPD), Alzheimer's disease, Parkinson's disease, atherosclerosis, chronic kidney disease (CKD), diabetes, gastroenteritis, rheumatoid arthritis, and the like.Type: GrantFiled: November 25, 2016Date of Patent: October 15, 2019Assignee: CHINA PHARMACEUTICAL UNIVERSITYInventors: Qidong You, Zhengyu Jiang, Mengchen Lu, Zhiyun Chen, Haopeng Sun, Xiaojin Zhang, Xiaoke Guo, Xiaoli Xu
-
APPLICATION OF NEURAMINIDASE AND INHIBITORS THEREOF IN MYOCARDIAL ISCHEMIA AND MYOCARDIAL INFARCTION
Publication number: 20190054055Abstract: The present invention discloses an application of neuraminidase and inhibitors thereof in myocardial ischemia and myocardial infarction, provides a correlation between neuraminidase and myocardial ischemic damage to prove the myocardial ischemic damage can be alleviated by inhibiting the activity of neuraminidase, and to prove the neuraminidase can be used as a target for screening drugs for preventing, alleviating and/or treating myocardial ischemic damage. The present invention also demonstrates the alleviating effect of neuraminidase inhibitors on myocardial ischemic damage. Neuraminidase inhibitors improves myocardial ischemic damage by reducing the level of neuraminidase. The present invention further provides a pharmaceutical preparation comprising neuraminidase inhibitor(s) and pharmaceutically acceptable carrier(s), the pharmaceutical preparation can be used for reducing the level of neuraminidase, thus improving myocardial ischemic damage.Type: ApplicationFiled: March 29, 2016Publication date: February 21, 2019Applicant: CHINA PHARMACEUTICAL UNIVERSITYInventors: Lianwen QI, Lei ZHANG, Tingting WEI, Yong FAN -
Publication number: 20190040029Abstract: The present invention relates to a type of aryl benzofuran amidated derivatives, the medical use thereof, and the preparation method; said derivatives have antioxidation activity, and xanthine oxidase inhibitory activity, and can be used for antioxidation and for preparing compositions, drugs and health products and treating gout and hyperuricemia.Type: ApplicationFiled: January 19, 2017Publication date: February 7, 2019Applicant: CHINA PHARMACEUTICAL UNIVERSITYInventor: Jun CHEN
-
Publication number: 20180251423Abstract: Compounds of formula (I) having 1-sulfonamido-4-aryloxy as a basic backbone. A preliminary activity test showed that the compounds provide excellent interference of a binding of Nrf2 by Keap1, thereby activating Nrf2. The compounds have a potential anti-inflammatory activity and can be used to treat a plurality of inflammation-associated diseases, including chronic obstructive pulmonary disease (COPD), Alzheimer's disease, Parkinson's disease, atherosclerosis, chronic kidney disease (CKD), diabetes, gastroenteritis, rheumatoid arthritis, and the like.Type: ApplicationFiled: November 25, 2016Publication date: September 6, 2018Applicant: CHINA PHARMACEUTICAL UNIVERSITYInventors: Qidong YOU, Zhengyu JIANG, Mengchen LU, Zhiyun CHEN, Haopeng SUN, Xiaojin ZHANG, Xiaoke GUO, Xiaoli XU
-
Publication number: 20180141974Abstract: A pentapeptide associated with integrin receptor ?v?3, which has a sequence of arginine-tryptophan-arginine-asparagine-methionine. The pentapeptide targets tumor cells highly expressing ?v?3, but not tumor cells lowly expressing ?v?3 and normal cells. Accordingly, the pentapeptide is useful in the diagnosis and treatment of cancers.Type: ApplicationFiled: October 26, 2015Publication date: May 24, 2018Applicant: CHINA PHARMACEUTICAL UNIVERSITYInventors: Yueqing GU, Congying ZHANG, Menglu ZHAO, Qian WANG, Caiping TIAN, Yuxi LIU
-
Patent number: 9943524Abstract: A new use of a compound as indicated in structural formula I in preparing medications for preventing and/or treating pulmonary fibrosis includes the compound having the structure as indicated in structural formula 1 that substantially reduces the inflammation of diseased lung tissue, lowers the concentration of fibrosis factors TGF-?I in diseased lung tissue, decreases the excessive deposition of collagen in diseased lung tissue, and has substantial prevention and treatment effectiveness against fibrosis.Type: GrantFiled: June 17, 2015Date of Patent: April 17, 2018Assignee: China Pharmaceutical UniversityInventors: Xianghong Xu, Mian Zhang, Juan Xiang, Yanhui He, Yan Wu
-
Patent number: 9822089Abstract: The present invention relates to the field of natural pharmaceutical chemistry, and in particular, to a resveratrol dimer (7R,8R)-trans-?-viniferin (I), a preparation process therefor and a purpose thereof in lowering a blood sugar level. According to the present invention, an R type of resveratrol dimer is separated from the resveratrol dimer by using high-speed countercurrent chromatography. Pharmacodynamic tests proved that the R type of resveratrol dimer has a better effect in lowering a blood sugar level than a racemate.Type: GrantFiled: June 5, 2014Date of Patent: November 21, 2017Assignee: China Pharmaceutical UniversityInventors: Lingyi Kong, Jianguang Luo, Chao Han, Xiaobing Wang, Hao Hong
-
Publication number: 20170292113Abstract: Disclosed are an inflammation-targeted neutrophil granulocyte drug delivery system and use thereof, wherein the drug delivery system includes neutrophil granulocytes and a therapeutic substance or a detectable substance loaded into the neutrophil granulocytes or onto the surface of the neutrophil granulocytes in a direct or indirect way. By using the neutrophil granulocytes as a carrier of a drug, the drug is actively targeted to an inflammatory site, thereby increasing the drug concentration at the inflammatory site. Under the stimulation of cytokines, the neutrophil granulocytes arriving at the inflammatory site are abnormally activated, disintegrate rapidly, and die in the way of “Neutrophil extracellular traps (NETs)”. This helps to rapidly release the loaded drug to the targeted site, so as to improve the therapeutic effect and reduce the toxic and side effects.Type: ApplicationFiled: November 27, 2014Publication date: October 12, 2017Applicant: CHINA PHARMACEUTICAL UNIVERSITYInventors: Can ZHANG, Jingwei XUE, Zekai ZHAO, Lei ZHANG, Yajing WEN
-
Publication number: 20160229828Abstract: The present invention relates to the field of natural pharmaceutical chemistry, and in particular, to a resveratrol dimer (7R,8R)-trans-?-viniferin (I), a preparation process therefor and a purpose thereof in lowering a blood sugar level. According to the present invention, an R type of resveratrol dimer is separated from the resveratrol dimer by using high-speed countercurrent chromatography. Pharmacodynamic tests proved that the R type of resveratrol dimer has a better effect in lowering a blood sugar level than a racemate.Type: ApplicationFiled: June 5, 2014Publication date: August 11, 2016Applicant: CHINA PHARMACEUTICAL UNIVERSITYInventors: Lingyi KONG, Jianguang LUO, Chao HAN, Xiaobing WANG, Hao HONG
-
Patent number: 8859527Abstract: Inclusion complex of deoxypodophyllotoxin of cyclodextrin, the preparation method and the use for the treatment of cancer thereof are disclosed. The inclusion complex consists of deoxypodophyllotoxin and beta-cyclodextrin derivative, wherein the molar ration of deoxypodophyllotoxin to beta-cyclodextrin derivative is 1:1-1:10. The beta-cyclodextrin derivative is sulfobutyl ether-beta-cyclodextrin or hydroxypropyl-beta-cyclodextrin.Type: GrantFiled: October 1, 2010Date of Patent: October 14, 2014Assignees: Zhejiang Jianfeng Pharmaceutical Holdings, China Pharmaceutical UniversityInventors: Xiong Zhu, Jinlong Huang, Baojin Wu, Houwei Luo, Zhiwu Yin, Changxuan Wu
-
Patent number: 8846752Abstract: Isoflavone fatty acid ester derivatives of formula (I) or (II), the preparation method thereof and the pharmaceutical compositions containing such compounds are disclosed. The uses of such compounds in preparation of medicaments for preventing or treating hyperlipidemia, obesity or type II diabetes are also disclosed.Type: GrantFiled: March 1, 2010Date of Patent: September 30, 2014Assignees: China Pharmaceutical University, Nanjing Medical University Affiliated Brain HospitalInventors: Hua Xiang, Wei Zhao, Hong Xiao, Yao Yao, Renling Ma, Lei Qian, Xiaobo Li, Qidong You, Qingjiang Liao
-
Patent number: 8664238Abstract: Indenoisoquinolinone derivatives (I), the manufacturing method and the medical use thereof, which belong to pharmaceutical chemistry and organic chemistry field, are disclosed. These compounds can be used for treating several medical symptoms related to postmenopausal syndrome, uterine fibers deterioration and aortic smooth muscle cells proliferation, especially ER-(+) depend breast cancer. Meanwhile, these compounds can also be used for treating glioma and lung cancer, and have inhibiting effect on tumor metastasis effect on tumor metastasis.Type: GrantFiled: December 16, 2009Date of Patent: March 4, 2014Assignees: China Pharmaceutical University, Nanjing Medical University Affiliated Brain HospitalInventors: Hua Xiang, Tianlin Wang, Hong Xiao, Qidong You, Yao Yao, Xiaobo Li, Qingjiang Liao
-
Patent number: 8501803Abstract: The present invention relates to a field of pharmaceutical chemistry, more specifically, the present invention relates to a garcinia derivative Formula (I), its preparing method, and medicinal use. Wherein the definitions of R1 and R2 are disclosed in the specification of the present invention, and the derivative of the present invention is a structurally simplified analogue of the gambogic acid compound; wherein the gambogic acid compound possesses anti-cancer characteristics, and could be used for preparation of anti-tumor drugs.Type: GrantFiled: November 9, 2010Date of Patent: August 6, 2013Assignee: China Pharmaceutical UniversityInventors: Qidong You, Xiaojian Wang, Qian Yang, Na Lu, Changjun Lin, Qinglong Guo
-
Publication number: 20130085140Abstract: Indenoisoquinolinone derivatives (I), the manufacturing method and the medical use thereof, which belong to pharmaceutical chemistry and organic chemistry field, are disclosed. These compounds can be used for treating several medical symptoms related to postmenopausal syndrome, uterine fibers deterioration and aortic smooth muscle cells proliferation, especially ER-(+) depend breast cancer. Meanwhile, these compounds can also be used for treating glioma and lung cancer, and have inhibiting effect on tumor metastasis effect on tumor metastasis.Type: ApplicationFiled: December 16, 2009Publication date: April 4, 2013Applicant: CHINA PHARMACEUTICAL UNIVERSITYInventors: Hua Xiang, Tianlin Wang, Hong Xiao, Qidong You, Yao Yao, Xiaobo Li, Qingjiang Liao